Enterprise transformation rarely fails because of strategy. It fails because of execution, and one of the most complex parts of execution is data migration.

In this episode, Mehmet speaks with Dominik Wittenbeck, CTO at SNP, about the real mechanics behind SAP transformations and why data migration is often the most underestimated phase of enterprise modernization.

They explore how organizations approach SAP migrations, the risks of underestimating data transformation projects, and why Selective Data Transition (SDT / Bluefield®) is becoming a preferred strategy for many enterprises.

The conversation also dives into how AI is beginning to reshape large-scale IT transformation projects, from presales and planning to testing and root cause analysis. Dominik shares practical insights on how AI can augment consultants rather than replace them, helping organizations manage increasingly complex system transformations with greater speed and accuracy.

⸻

About the Guest

Dominik Wittenbeck is CTO at SNP Schneider-Neureither & Partner SE with over 20 years of experience in SAP-centric enterprise transformations. His focus is Selective Data Transition (SDT / Bluefield®) and scaling scarce migration expertise through structured methods and AI-supported orchestration.

Connect with him on LinkedIn:

https://www.linkedin.com/in/dominik-wittenbeck-61a64669/

⸻

About SNP

SNP is a global software and consulting company specializing in data transformation, system landscape modernization, and SAP migrations. With its Kyano® platform, SNP enables complex transformations in a structured, rule-based, and scalable way.

More:

https://www.snpgroup.com/

⸻

Key Takeaways

• Data migration is often the most underestimated element of digital transformation projects.

• Selective Data Transition (SDT / Bluefield®) offers a middle ground between greenfield implementations and full system conversions.

• AI can significantly accelerate presales, documentation, and root cause analysis in complex IT transformations.

• Automation and AI are augmenting consultants rather than replacing them, enabling teams to manage more projects at scale.

• Structured transformation platforms and methodologies are becoming essential as enterprise change accelerates globally.

⸻

What You Will Learn

• Why SAP migrations remain one of the most complex enterprise IT initiatives

• The differences between greenfield, brownfield, and selective data transition approaches

• How AI is being used today in data migration planning and execution

• The hidden risks that organizations face when migration projects are underestimated

• How enterprises can scale transformation expertise despite the shortage of experienced consultants

⸻

Episode Highlights (Chapters)

00:00 Introduction and Dominik’s background

01:00 Why data migration expertise is scarce

05:00 Why migration projects often scare IT teams

09:00 Misalignment between IT and business in transformation projects

14:00 What Selective Data Transition (Bluefield®) means

18:00 The biggest risks when data migration is underestimated

21:00 Where AI is already helping transformation teams

27:00 How AI improves project handovers and knowledge transfer

30:00 Ensuring deterministic and auditable data transformations

33:00 Using AI for root cause analysis in migration projects

36:00 MCP servers, agents, and AI orchestration

38:00 AI-powered testing and validation

41:00 The knowledge loss problem in consulting projects

45:00 The future of AI in enterprise transformation

48:00 Will AI replace consultants? Dominik’s perspective

52:00 Staying relevant in the age of AI

What if aging is not inevitable, but a solvable biological problem?

In this episode of The CTO Show with Mehmet, Mehmet sits down with Dr. Bill Andrews, a renowned molecular geneticist and pioneer in telomere research. Dr. Andrews has spent decades studying the mechanisms of aging and is known for leading discoveries around telomerase, the enzyme connected to cellular aging.

The conversation explores the biological root causes of aging, the role of telomeres in limiting human lifespan, and the scientific pursuit of extending human healthspan. Dr. Andrews also shares insights into the challenges of biotech innovation, the economics of pharmaceutical research, and why breakthroughs in longevity science often struggle to reach the public.

This episode bridges biology, technology, and the future of human health, offering a deep dive into one of the most fascinating scientific frontiers of our time.

⸻

About the Guest

Dr. Bill Andrews is a molecular biologist and geneticist recognized for his groundbreaking work in telomere and telomerase research. Over his career, he has contributed to the discovery and development of multiple biotechnology innovations, including therapies related to cancer and genetic diseases.

Dr. Andrews holds more than 50 patents in genetics and biotechnology and has dedicated his career to understanding the biological mechanisms of aging and developing solutions to extend healthy human lifespan.

He is the founder of Sierra Sciences, a biotechnology company focused on discovering ways to activate telomerase and address the root causes of aging.

https://www.linkedin.com/in/william-h-andrews-ceo-5455b45/

⸻

Key Takeaways

• Aging may be driven by the shortening of telomeres, protective caps at the ends of chromosomes.

• The Hayflick Limit suggests human cells can only divide a finite number of times.

• Telomerase is an enzyme that can extend telomeres, potentially slowing or reversing aspects of aging.

• Longevity research faces major challenges due to funding structures and biotech investment models.

• Many scientists believe extending healthspan, not just lifespan, should be the primary goal of longevity science.

• Advances in biotechnology could eventually transform aging from an inevitability into a treatable biological process.

⸻

What You Will Learn

• Why aging occurs from an evolutionary and genetic perspective

• How telomeres influence cellular aging and lifespan

• The role of telomerase in longevity research

• Why curing aging is scientifically complex and financially challenging

• The relationship between aging and diseases such as cancer and Alzheimer’s

• How biotech innovation may shape the future of human longevity

⸻

Episode Highlights

00:00 Introduction to Dr. Bill Andrews and longevity research

02:00 Why humans age from an evolutionary perspective

06:30 Healthspan vs lifespan and the goals of longevity science

10:00 The Hayflick Limit and the biological clock of cells

13:30 Discovering telomeres and telomerase

18:00 The search for molecules that activate telomerase

22:00 How scientists measure aging and longevity

27:00 Why curing aging is scientifically and financially difficult

34:00 The role of pharmaceutical companies and research incentives

41:00 The economics of biotech innovation

48:00 Longevity research in animals and pets

55:00 The broader vision for curing aging

⸻

Resources Mentioned

• Sierra Sciences: https://sierrasci.com/

• Up One Podcast: https://podcasts.apple.com/us/podcast/up-one/id1815282315?ls=1

In this episode of The CTO Show with Mehmet, Mehmet Gonullu sits down with Betsy Atkins, serial entrepreneur, board member of global companies, and advisor to leading organizations including Google Cloud.

The conversation explores how the role of the board is evolving in an era defined by AI, agentic systems, and accelerating technological change. Betsy shares deep insights on how boards must move from passive oversight to active orchestration, the risks introduced by agentic AI, and what leaders must do today to stay relevant.

From “corporate cholesterol” slowing down organizations to the emergence of AI governance frameworks, this episode offers a candid look at the challenges and opportunities shaping the next generation of leadership.

⸻

👤 About the Guest

Betsy Atkins is a three-time CEO, serial entrepreneur, and globally recognized corporate governance expert. She has served on over 30 public and private company boards and currently sits on the Google Cloud Advisory Board, as well as boards including Wynn Resorts and goPuff.

Betsy brings decades of experience across venture capital, private equity, and public markets, advising leadership teams on digital transformation, governance, and innovation.

⸻

🔑 Key Takeaways

• Boards are shifting from passive oversight to active involvement in technology and innovation

• Agentic AI introduces new risks that require structured governance and monitoring

• “Corporate cholesterol” slows companies down as they scale and must be actively removed

• AI governance will become as critical as cybersecurity oversight

• Founder-led companies must carefully select board members based on mindset, not just resumes

• Decision speed and adaptability are now core competitive advantages

• There is currently no clear “kill switch” for agentic AI systems, creating new risk categories

• Investors must rethink due diligence to properly evaluate AI-driven companies

⸻

📚 What You Will Learn

• How the role of the board is evolving in the age of AI

• The concept of “corporate cholesterol” and how it impacts growth

• How to build AI governance frameworks inside organizations

• The real risks behind agentic AI and autonomous systems

• What founders should look for when building their boards

• How investors should evaluate AI capabilities during due diligence

• Why execution speed is becoming a key differentiator

• The future of leadership in an AI-driven world

⸻

⏱️ Episode Highlights

00:00 Introduction and Betsy Atkins’ background

02:45 How boards have evolved from oversight to active engagement

05:30 The concept of “corporate cholesterol” and organizational drag

08:40 Innovation vs. risk in public and private companies

11:00 Founder-led boards and selecting the right directors

17:30 AI’s impact on organizational structure and decision-making

21:00 Agentic AI risks and real-world experiments

25:00 Balancing innovation and governance in AI adoption

30:00 Who owns AI governance inside the organization

33:00 The need for monitoring, orchestration, and control systems

35:30 The “kill switch” debate and future AI risk

40:30 AI due diligence for investors and common mistakes

44:30 Key technology trends shaping the next decade

48:00 Optimism vs. risk in the future of AI

⸻

🔗 Resources Mentioned

• Betsy Atkins Website: https://betsyatkins.com/

• Betsy Atkins LinkedIn: https://www.linkedin.com/in/betsy-atkins-a36b114/

• Anthropic research on AI agent behavior: https://www.anthropic.com/research/agentic-misalignment